Stryker Corp
SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 19/3024% below fair value
$306.81+14.95 (+5.12%)
Close on Nov 2, 2026Market cap $117.68BP/E 32.7Yield –
Stryker Legacy Neurotechnology & Spine Segment by Quarter
Legacy Neurotechnology & Spine Segment (through FY2021Q3) — Worldwide Sales ($M) ($M)
Stryker Legacy Neurotechnology & Spine Segment: $876M in Q3 2021, up 6.8% from a year earlier. No newer figure appears in the documents we track.
Latest, Q3 2021
876
Period ended Sep 30, 2021
Change on a year earlier
+6.8%
820 in Q3 2020
History
16 quarters
Since Q4 2017
Sources
12
Documents cited below
Where the Q3 2021 figure comes from
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Stryker Legacy Neurotechnology & Spine Segment ($M), quarterly Q4 2017–Q3 2021 [Data set]. Compiled from Stryker SEC filings and investor materials. https://stockdatahq.com/stocks/syk/kpis/leg-ns-seg-only
See every metric in the Stryker KPI table. Data updated Nov 2, 2026.